{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:40:31Z","timestamp":1793580031074,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11523-025-01177-x","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:12:45Z","timestamp":1762762365000},"page":"967-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-1314","authenticated-orcid":false,"given":"Melissa L.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker R.","family":"Dakhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Thaddeus","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahad","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh M.","family":"Mugundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliann","family":"Chmielecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"3","key":"1177_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"1177_CR2","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"issue":"21","key":"1177_CR3","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1810865.","journal-title":"N Engl J Med"},{"issue":"19","key":"1177_CR4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"8","key":"1177_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.21037\/atm.2018.04.04","volume":"6","author":"P Baxevanos","year":"2018","unstructured":"Baxevanos P, Mountzios G. Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau? Ann Transl Med. 2018;6(8):139. https:\/\/doi.org\/10.21037\/atm.2018.04.04.","journal-title":"Ann Transl Med."},{"issue":"9","key":"1177_CR6","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/jco.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589\u201397. https:\/\/doi.org\/10.1200\/jco.2004.08.163.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1177_CR7","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/cncr.23902","volume":"113","author":"CP Belani","year":"2008","unstructured":"Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008;113(9):2512\u20137. https:\/\/doi.org\/10.1002\/cncr.23902.","journal-title":"Cancer"},{"key":"1177_CR8","doi-asserted-by":"publisher","unstructured":"Esposito F, Giuffrida R, Raciti G, Puglisi C, Forte S. Wee1 kinase: a potential target to overcome tumor resistance to therapy. Int J Mol Sci. 2021;22(19):10689. https:\/\/doi.org\/10.3390\/ijms221910689.","DOI":"10.3390\/ijms221910689"},{"issue":"17","key":"1177_CR9","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1158\/1078-0432.Ccr-11-0650","volume":"17","author":"KA Bridges","year":"2011","unstructured":"Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011;17(17):5638\u201348. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-0650.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1177_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.neo.2015.09.006","volume":"17","author":"T Kausar","year":"2015","unstructured":"Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, et al. Sensitization of pancreatic cancers to gemcitabine chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair. Neoplasia. 2015;17(10):757\u201366. https:\/\/doi.org\/10.1016\/j.neo.2015.09.006.","journal-title":"Neoplasia"},{"issue":"9","key":"1177_CR11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/1078-0432.Ccr-10-2580","volume":"17","author":"NV Rajeshkumar","year":"2011","unstructured":"Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011;17(9):2799\u2013806. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2580.","journal-title":"Clin Cancer Res"},{"issue":"10271","key":"1177_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0140-6736(20)32554-x","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10271):281\u201392. https:\/\/doi.org\/10.1016\/s0140-6736(20)32554-x.","journal-title":"Lancet"},{"issue":"14","key":"1177_CR13","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/jco.20.03167","volume":"39","author":"JF Liu","year":"2021","unstructured":"Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, et al. Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol. 2021;39(14):1531\u20139. https:\/\/doi.org\/10.1200\/jco.20.03167.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1177_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1177_CR15","unstructured":"Siu C, Lan G. Flexible interim analysis method for sample size re-estimation and early stopping: a conditional power approach. Proceedings of the Annual Meeting of the American Statistical Association, August 5-9, 2001. 2001. https:\/\/www.researchgate.net\/publication\/267975514_Flexible_interim_analysis_method_for_sample_size_re-estimation_and_early_stopping_a_conditional_power_approach. Accessed 4 Sep 2025."},{"key":"1177_CR16","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","author":"US Department of Health and Human Services","year":"2010","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Bethesda: US Department of Health and Human Services; 2010."},{"key":"1177_CR17","unstructured":"National Cancer Institute. The TP53 database. 2025. https:\/\/tp53.cancer.gov\/. Accessed 12 Aug 2025."},{"issue":"14","key":"1177_CR18","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100(14):8424\u20139. https:\/\/doi.org\/10.1073\/pnas.1431692100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"1177_CR19","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/jco.2016.67.5942","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34(36):4354\u201361. https:\/\/doi.org\/10.1200\/jco.2016.67.5942.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1177_CR20","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1200\/jco.2015.33.15_suppl.5506","volume":"33","author":"AM Oza","year":"2015","unstructured":"Oza AM, Weberpals JI, Provencher DM, Grischke E-M, Hall M, Uyar D, et al. An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P\/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer. J Clin Oncol. 2015;33(15_suppl):5506. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.5506.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1177_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1753465815617871","volume":"10","author":"M Shea","year":"2016","unstructured":"Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10(2):113\u201329. https:\/\/doi.org\/10.1177\/1753465815617871.","journal-title":"Ther Adv Respir Dis"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01177-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:10:25Z","timestamp":1764605425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01177-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01177-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Reference 8 updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Melissa L. Johnson is an employee of Sarah Cannon Research Institute; has received research funding from AbbVie, Acerta, Adaptimmune, Apexigen, Array BioPharma, AstraZeneca, Atreca, BeiGene, Birdie, Boehringer Ingelheim, Checkpoint Therapeutics, Corvus Pharmaceuticals, CytomX, Daiichi Sankyo, Dynavax, Lilly, EMD Serono, Genentech\/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Hengrui Therapeutics, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Loxo Oncology, Lycera, Merck, Mirati Therapeutics, Neovia Oncology, Novartis, OncoMed Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Sanofi, Shattuck Labs, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, University of Michigan, WindMIL, TCR2 Therapeutics, Arcus Biosciences, Ribon Therapeutics, and Amgen; and has acted as a consultant for\u00a0AbbVie, Achilles Therapeutics, AstraZeneca, Atreca, Boehringer Ingelheim, Calithera Biosciences, Genentech, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Incyte, Janssen, Lilly, Loxo Oncology, Merck, Mirati Therapeutics, Novartis, Pfizer, Ribon Therapeutics, Sanofi, and the Association of Community Cancer Centers. Shaker R. Dakhil, J. Thaddeus Beck, Ahad Sadiq, and Smitha Menon have no conflicts of interest to declare. Ganesh M. Mugundu and Juliann Chmielecki are former employees of and equity holders in AstraZeneca. David R. Spigel is an employee of Sarah Cannon Research Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The trials were conducted according to the ethical principles of the Declaration of Helsinki and were approved by the institutional review boards of each participating site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"These clinical trials obtained informed consent from all participating patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca\u2019s data sharing policy described at\n                      \n                      .\u202fData for studies directly listed on Vivli can be requested through Vivli at\n                      \n                      . Data for studies not listed on Vivli can be requested through Vivli at\n                      \n                      . The AstraZeneca Vivli member page is also available, outlining further details:\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data And Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design: MLJ, GMM, JC, and DRS. Development of methodology: MLJ, GMM, JC, and DRS. Acquisition of data (acquired and managed patients, provided facilities, etc.): MLJ, SRD, JTB, AS, and SM. Analysis and interpretation of data (e.g., statistical analysis, computational analysis): MLJ, GMM, JC, and DRS. Writing, review, and\/or revision of the manuscript: all authors. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): MLJ, GMM, JC, and DRS. Study supervision: MLJ, SRD, JTB, AS, and SM.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}